Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
Table 3
Summary of the meta-analysis results.
Categories
Trials (patients)
HR (95% CI)
(%)
OS (all)
17 (2858)
1.68 (1.24-2.27)R
82.9%
<0.001
3.35
0.001
Study region
0.474
Eastern countries
13 (1559)
1.79 (1.24-2.58)R
83.1%
<0.001
3.11
0.002
Western countries
4 (1299)
1.39 (0.78-2.48)R
83.4%
<0.001
1.11
0.267
Cancer type
0.641
OC
2 (156)
4.60 (2.05-10.34)F
13.6%
0.282
3.69
<0.001
OSC
2 (200)
2.07 (1.43-2.98)F
0.0%
0.683
3.89
<0.001
GC
2 (309)
2.00 (1.44-2.79)F
0.0%
0.357
4.11
<0.001
CCA
2 (389)
1.23 (0.32-4.69)R
88.9%
0.003
0.31
0.757
ESCC
2 (258)
0.82 (0.45-1.50)R
60.9%
0.110
0.64
0.521
BC
2 (1154)
0.83 (0.66-1.04)F
0.0%
0.388
1.60
0.111
Others
5 (392)
2.27 (1.72-3.00)F
0.0%
0.736
5.77
<0.001
TNM stage
0.601
I-IV
11 (1113)
2.03 (1.38-2.98)R
75.4%
0.001
3.62
<0.001
I-III
4 (1354)
1.27 (0.77-2.10)R
83.4%
<0.001
0.95
0.341
I
1 (90)
2.41 (1.29-4.50)R
—
—
2.76
0.006
NR
1 (301)
0.66 (0.50-0.88)R
—
—
2.86
0.004
Sample size
0.010
≥300
3 (1455)
0.76 (0.64-0.91)F
11.0%
0.325
8.96
<0.001
<300
13 (1403)
2.03 (1.51-2.74)R
69.9%
0.001
4.67
<0.001
Analysis method
0.034
Multivariate
14 (2564)
1.82 (1.28-2.58)R
83.4%
<0.001
3.34
0.001
Univariate
3 (294)
1.24 (0.61-2.53)R
86.9%
<0.001
0.59
0.555
DFS (all)
10 (1908)
1.88 (1.31-2.70)R
76.8%
<0.001
3.43
0.001
OC: ovarian cancer; OSC: osteosarcoma; GC: gastric cancer; CCA: cholangiocarcinoma; ESCC: esophageal squamous cell carcinoma; BC: breast cancer; others including colorectal cancer, pancreatic cancer, hepatocellular carcinoma, gallbladder cancer, and non-small cell lung cancer; F: fixed effects; R: random effects; NR: none reported; OS overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; : value for statistical significance based on test; : value for heterogeneity based on test; : value for statistical outcome based on multivariate metaregression analysis.
